Product image of Memantina Aurovitas (Memantine Hydrochloride) supplied by GNH India

Memantina Aurovitas

Active Ingredient:
Memantine Hydrochloride
Origin:
EU

Memantina Aurovitas (Memantine Hydrochloride)

Memantine, the active ingredient in Memantina Aurovitas, is an NMDA receptor antagonist presented as an oral tablet for oral use. It treats moderate to severe Alzheimer’s disease in adult patients by helping to preserve cognitive function and daily activities.

GNH India supplies Memantina Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from consistent product availability and regulatory support across multiple regions.

Manufacturer / TM Owner

Aurovitas Spain,s.A.U.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Memantina Aurovitas (memantine) is employed in the therapeutic approach to neurodegenerative disorders, specifically targeting the glutamatergic excitotoxic pathway implicated in Alzheimer’s disease. By modulating NMDA receptor activity, it helps to stabilize neuronal function and mitigate progressive cognitive decline.
  • Alzheimer's disease (moderate to severe): Improves cognition, functional abilities, and overall daily performance in affected patients.

How It Works

  • Memantine acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor. By binding within the receptor-associated ion channel, it reduces excessive calcium influx caused by overstimulation of glutamate, thereby decreasing excitotoxic neuronal injury. This modulation occurs without completely blocking normal synaptic transmission, allowing essential physiological signaling while protecting neurons from pathological overactivation.

Side Effects

Memantina Aurovitas may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Dizziness
  • Headache
  • Constipation

Serious or Rare Side Effects

  • Seizures
  • Severe allergic reactions (e.g., rash, angioedema)
  • Stevens‑Johnson syndrome or toxic epidermal necrolysis

Precautions & Warnings

When prescribing Memantina Aurovitas, clinicians should consider several safety factors.

  • Renal impairment: Adjust dose or monitor renal function closely.
  • Hepatic impairment: Use with caution; monitor liver enzymes.
  • History of seizures: Evaluate risk; may increase seizure frequency.
  • Cardiovascular disease: Monitor blood pressure and heart rate regularly.
  • Concomitant NMDA antagonists: Avoid combined use to prevent additive neuro‑inhibition.
  • Store at room temperature: Keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Memantina Aurovitas can interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid)

  • Other NMDA antagonists (e.g., amantadine, dextromethorphan): May cause excessive inhibition.
  • Strong CYP450 inducers (e.g., carbamazepine, phenytoin): Reduce memantine plasma levels.
  • Drugs that lower seizure threshold (e.g., bupropion): Increase risk of seizures.

Moderate Interactions (Monitor Closely)

  • Antihypertensive agents: Memantine may enhance hypotensive effect.
  • Anticholinergic medications: May blunt cognitive benefits.
  • Selective serotonin reuptake inhibitors (SSRIs): Potential for increased serotonergic activity.

Frequently Asked Questions

Memantina Aurovitas contains memantine hydrochloride and is prescribed for the treatment of moderate to severe Alzheimer’s disease. It helps to improve cognition and daily functioning by reducing glutamate‑mediated excitotoxic damage in the brain.

Memantine works as a non‑competitive antagonist of the NMDA receptor. By blocking the receptor‑associated ion channel, it limits excessive calcium entry caused by overstimulation of glutamate, thereby protecting neurons from excitotoxic injury while preserving normal synaptic activity.

The dosage of Memantina Aurovitas is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. The prescriber will select the appropriate strength and titration schedule according to approved guidelines.

Safety data for memantine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA‑receptor antagonist class, whereas other approved agents such as cholinesterase inhibitors (donepezil, rivastigmine) act by enhancing acetylcholine signaling. Memantine is typically used in moderate to severe stages and may be combined with a cholinesterase inhibitor for additive benefit.

Store the tablets at room temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat and direct sunlight to maintain product stability.

The medication is taken orally, usually with or without food, as directed by the prescribing physician. Tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious adverse events, although uncommon, include seizures, severe allergic reactions such as anaphylaxis, and life‑threatening skin conditions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Memantina Aurovitas is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA‑receptor antagonists.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Memantine Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT